News
The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...
Of these, 34 will receive a one-time subretinal injection of OCU410ST (200 μL at a concentration of 1.5 × 10¹¹ vector genomes/mL ... trial represents a major advancement as Ocugen's second late-stage ...
Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
WASHINGTON — A closely divided Supreme Court refused Monday to hear a 2nd Amendment challenge to the bans on semiautomatic ...
A new petition filed with the Supreme Court on Friday asks the justices to find a nearly 100-year-old firearm regulation ...
Calling it a “generational win,” Second Amendment advocates are cheering the removal of several weapons from the National ...
A new generation of Second Amendment supporters no longer visits shooting ranges or joins the NRA — instead, it circulates ...
Gun control challenges at the Supreme Court have provided uneven results in this term, but several major gun law questions ...
The case tested the reach of the 2nd Amendment and its “right to keep and bear arms.” WASHINGTON — A closely divided Supreme Court refused Monday to hear a 2nd Amendment challenge to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results